Bevacizumab Injection officially approved by Indonesia’s National Agency of Drug and Food Control (BPOM), following Nigeria, Pakistan, and Colombia – accelerating global commercialization Approval in ASEAN’s largest pharma market strengthens BioDlink’s position as a global supplier of antibody/XDC therapies via international GMP standards and commercial capabilities
SUZHOU, China, Aug. 21, 2025 /PRNewswire/ — BioDlink announced that its Bevacizumab Injection has obtained marketing authorization from Indonesia’s National Agency of Drug and Food Control (BPOM). This marks BioDlink’s fourth international approval within two months – following Nigeria, Pakistan, and Colombia – signaling accelerated BioDlink’s global expansion into a sustained commercialization phase.
Strategic Significance of Indonesian ApprovalIndonesia, the world’s fourth-most populous nation, reports over 400,000 new cancer cases annually (WHO). Yet biologics accessibility remains below 15%. As ASEAN’s largest pharmaceutical market and regulatory hub, this approval expedites regional market access across Southeast Asia. BioDlink’s cost-effective bevacizumab, manufactured in China in compliance with international GMP standards, is helping to address critical treatment gaps for patients in Indonesia.
Global Standards, Proven Quality & ComplianceBPOM’s rigorous review process, fully aligned with PIC/S international standards, reinforces the clinical value of bevacizumab while reaffirming BioDlink’s world-class quality systems. Our manufacturing facility is GMP-certified across multiple regions—including China, Brazil, Egypt, Indonesia, Colombia, Argentina, and Pakistan—and recognized by Japan’s PMDA. This comprehensive accreditation ensures end-to-end compliance for antibodies, ADCs/XDCs, and biosimilar products.
This approval has proven BioDlink’s mature global commercialization capabilities:
Manufacturing Scale: Four commercial-scale manufacturing lines at the Suzhou site ensure a reliable global supply of antibodies, ADCs/XDCs, and biosimilars. Regulatory Excellence: BPOM’s PIC/S-aligned approval stands as a global benchmark, underscoring the strength of BioDlink’s quality systems. Strategic Momentum: Successive approvals across four markets are driving accelerated expansion in Southeast Asia and Latin America.
Dr. Jun Liu, Chief Executive Officer and Executive Director of BioDlink, stated:"These consecutive approvals demonstrate the strength of our quality systems and commercial execution. With Indonesia as a key ASEAN hub, and in close partnership with Kexing Biopharm, we are shifting from single-market breakthroughs to regional impact —expanding access, diversifying growth, and delivering affordable, high-quality therapies worldwide."
About BioDlink
BioDlink, a leading global Contract Development and Manufacturing Organization (CDMO) specializing in biologics, is committed to being the trusted partner of choice for biopharmaceutical innovators worldwide. Leveraging our advanced one-base integrated platform, BioDlink delivers end-to-end CDMO services for protein-based therapeutics (such as mAb, BsAb), biosimilar, and bioconjugated drugs (such as XDCs/ADCs) from early-stage research through to commercial-scale manufacturing.
BioDlink operates large-scale biopharmaceutical manufacturing facilities compliant with GMP standards and adheres to international quality management systems aligned with regulatory requirements in the US, the EU, and China. With our cutting-edge technology platforms and expert teams, BioDlink facilitates accelerated development timelines, with clients spanning Europe, the Americas, Asia, and several key emerging markets.
BioDlink operates with a clear service philosophy: "Quality-Driven, Innovation-Enabled, Growth-Shared," and has assembled an experienced and forward-thinking team. Committed to rigorous quality and compliance, the company nurtures a collaborative ecosystem that empowers its partners and delivers shared success. For more information, please visit: https://biodlink.com/
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
